{"id":"https://openalex.org/W2946024019","doi":"https://doi.org/10.2147/ijn.s139450","title":"CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","display_name":"CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","publication_year":2019,"publication_date":"2019-05-01","ids":{"openalex":"https://openalex.org/W2946024019","doi":"https://doi.org/10.2147/ijn.s139450","mag":"2946024019","pmid":"https://pubmed.ncbi.nlm.nih.gov/31213803","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6537039"},"language":"en","primary_location":{"id":"doi:10.2147/ijn.s139450","doi":"https://doi.org/10.2147/ijn.s139450","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ijn.s139450","pdf_url":"https://www.dovepress.com/getfile.php?fileID=50017","source":{"id":"https://openalex.org/S101287785","display_name":"International Journal of Nanomedicine","issn_l":"1176-9114","issn":["1176-9114","1178-2013"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Nanomedicine","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/getfile.php?fileID=50017","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109840679","display_name":"Lawrence D. Mayer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101297","display_name":"Jazz Pharmaceuticals (United States)","ror":"https://ror.org/019rsbe67","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101297","https://openalex.org/I4210152300"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Lawrence D Mayer","raw_affiliation_strings":["Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA","institution_ids":["https://openalex.org/I4210101297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075335611","display_name":"Paul G. Tardi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101297","display_name":"Jazz Pharmaceuticals (United States)","ror":"https://ror.org/019rsbe67","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101297","https://openalex.org/I4210152300"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Paul Tardi","raw_affiliation_strings":["Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA","institution_ids":["https://openalex.org/I4210101297"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110481152","display_name":"Arthur Chin Louie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101297","display_name":"Jazz Pharmaceuticals (United States)","ror":"https://ror.org/019rsbe67","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101297","https://openalex.org/I4210152300"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Arthur C Louie","raw_affiliation_strings":["Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA","institution_ids":["https://openalex.org/I4210101297"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5075335611","https://openalex.org/A5109840679","https://openalex.org/A5110481152"],"corresponding_institution_ids":["https://openalex.org/I4210101297"],"apc_list":{"value":2836,"currency":"USD","value_usd":2836},"apc_paid":{"value":2836,"currency":"USD","value_usd":2836},"fwci":1.0393,"has_fulltext":true,"cited_by_count":138,"citation_normalized_percentile":{"value":0.68981481,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"Volume 14","issue":null,"first_page":"3819","last_page":"3830"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cpx-351","display_name":"CPX-351","score":0.9980000257492065},{"id":"https://openalex.org/keywords/vyxeos","display_name":"Vyxeos","score":0.9919999837875366},{"id":"https://openalex.org/keywords/liposomal-chemotherapy","display_name":"liposomal chemotherapy","score":0.8960000276565552},{"id":"https://openalex.org/keywords/daunorubicin","display_name":"daunorubicin","score":0.9750000238418579},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":1.0},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9890000224113464},{"id":"https://openalex.org/keywords/co-formulation","display_name":"co-formulation","score":0.6679999828338623},{"id":"https://openalex.org/keywords/liposome-biodistribution","display_name":"liposome biodistribution","score":0.6460000276565552},{"id":"https://openalex.org/keywords/tumor-cell-uptake","display_name":"tumor cell uptake","score":0.9350000023841858},{"id":"https://openalex.org/keywords/p-glycoprotein-efflux","display_name":"P-glycoprotein efflux","score":0.7129999995231628},{"id":"https://openalex.org/keywords/chemoresistance","display_name":"chemoresistance","score":0.734000027179718},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.597000002861023},{"id":"https://openalex.org/keywords/distearoylphosphatidylcholine","display_name":"distearoylphosphatidylcholine","score":0.8349999785423279},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.3319999873638153}],"concepts":[{"id":"https://openalex.org/C2781021840","wikidata":"https://www.wikidata.org/wiki/Q411659","display_name":"Daunorubicin","level":3,"score":0.8990208506584167},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.852810263633728},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6565971970558167},{"id":"https://openalex.org/C185154212","wikidata":"https://www.wikidata.org/wiki/Q410454","display_name":"Liposome","level":2,"score":0.6294641494750977},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4616817831993103},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.44516676664352417},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4332254230976105},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.42461609840393066},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.41669419407844543},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.22302401065826416},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.103147953748703}],"mesh":[{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D003630","descriptor_name":"Daunorubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003630","descriptor_name":"Daunorubicin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D003630","descriptor_name":"Daunorubicin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004339","descriptor_name":"Drug Compounding","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D004705","descriptor_name":"Endocytosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008081","descriptor_name":"Liposomes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D014018","descriptor_name":"Tissue Distribution","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false}],"locations_count":6,"locations":[{"id":"doi:10.2147/ijn.s139450","doi":"https://doi.org/10.2147/ijn.s139450","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ijn.s139450","pdf_url":"https://www.dovepress.com/getfile.php?fileID=50017","source":{"id":"https://openalex.org/S101287785","display_name":"International Journal of Nanomedicine","issn_l":"1176-9114","issn":["1176-9114","1178-2013"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Nanomedicine","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5544406","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6537039","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6537039","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6537039","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int J Nanomedicine","raw_type":"Text"},{"id":"pmid:31213803","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31213803","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International journal of nanomedicine","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:6cfd77ea067b482db2d4c973b6435aac","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/6cfd77ea067b482db2d4c973b6435aac","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"International Journal of Nanomedicine, Vol Volume 14, Pp 3819-3830 (2019)","raw_type":"article"},{"id":"pmh:oai:dovepress.com/45968","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/cpx-351-a-nanoscale-liposomal-co-formulation-of-daunorubicin-and-cytar-peer-reviewed-article-IJN","pdf_url":null,"source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Review"}],"best_oa_location":{"id":"doi:10.2147/ijn.s139450","doi":"https://doi.org/10.2147/ijn.s139450","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ijn.s139450","pdf_url":"https://www.dovepress.com/getfile.php?fileID=50017","source":{"id":"https://openalex.org/S101287785","display_name":"International Journal of Nanomedicine","issn_l":"1176-9114","issn":["1176-9114","1178-2013"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Nanomedicine","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320312570","display_name":"Jazz Pharmaceuticals","ror":"https://ror.org/055mhsv54"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2946024019.pdf","grobid_xml":"https://content.openalex.org/works/W2946024019.grobid-xml"},"referenced_works_count":51,"referenced_works":["https://openalex.org/W203809443","https://openalex.org/W207118996","https://openalex.org/W1192950784","https://openalex.org/W1568498224","https://openalex.org/W1624224113","https://openalex.org/W1970039100","https://openalex.org/W1989789824","https://openalex.org/W1994267136","https://openalex.org/W1995357901","https://openalex.org/W1999130958","https://openalex.org/W1999705499","https://openalex.org/W2009570513","https://openalex.org/W2024937262","https://openalex.org/W2028323816","https://openalex.org/W2034058960","https://openalex.org/W2055884944","https://openalex.org/W2060262609","https://openalex.org/W2066864375","https://openalex.org/W2077945404","https://openalex.org/W2082440968","https://openalex.org/W2090297795","https://openalex.org/W2090715900","https://openalex.org/W2092355558","https://openalex.org/W2097192169","https://openalex.org/W2099065855","https://openalex.org/W2102423175","https://openalex.org/W2103562758","https://openalex.org/W2111724321","https://openalex.org/W2115906186","https://openalex.org/W2119367939","https://openalex.org/W2136112505","https://openalex.org/W2136923586","https://openalex.org/W2142229639","https://openalex.org/W2144520999","https://openalex.org/W2145952139","https://openalex.org/W2147860795","https://openalex.org/W2158240777","https://openalex.org/W2162351643","https://openalex.org/W2182695244","https://openalex.org/W2336887413","https://openalex.org/W2394130347","https://openalex.org/W2438771022","https://openalex.org/W2526672530","https://openalex.org/W2536634671","https://openalex.org/W2566711870","https://openalex.org/W2600452401","https://openalex.org/W2766330759","https://openalex.org/W2790178918","https://openalex.org/W2883399820","https://openalex.org/W2945792041","https://openalex.org/W4231346141"],"related_works":["https://openalex.org/W2555266496","https://openalex.org/W2016375132","https://openalex.org/W2332981905","https://openalex.org/W2082440968","https://openalex.org/W2058863425","https://openalex.org/W3046856303","https://openalex.org/W2136112505","https://openalex.org/W2801436543","https://openalex.org/W3040958666","https://openalex.org/W4410842570"],"abstract_inverted_index":{"Combination":[0],"regimens":[1,14],"are":[2,15,238],"a":[3,45,85,115,122,201,262,295],"standard":[4],"of":[5,12,49,78,84,90,109,135,156,192,213,223,241,250,265,267,275],"care":[6],"for":[7,67,205],"many":[8],"cancers.":[9],"However,":[10],"components":[11],"such":[13],"typically":[16],"first":[17],"developed":[18],"individually":[19],"and":[20,51,92,112,119,137,143,167,171,197,199,225,244,256,284],"subsequently":[21],"combined":[22],"using":[23],"strategies":[24,35],"to":[25,34,57,106,246,294],"minimize":[26],"toxicity.":[27],"Little":[28],"or":[29],"no":[30],"consideration":[31],"is":[32,44,80,104],"given":[33],"that":[36,53,219,292],"potentially":[37,232],"maximize":[38],"efficacy.":[39],"In":[40,181],"contrast,":[41],"CPX-351":[42,79,101,163,193,276],"(Vyxeos\u00ae)":[43],"dual-drug":[46],"liposomal":[47],"encapsulation":[48],"cytarabine":[50,91,136,166,196,224],"daunorubicin":[52,93,168,198,226],"was":[54],"rationally":[55],"designed":[56],"improve":[58],"efficacy":[59,77,274],"over":[60,206],"the":[61,95,150,162,178,189,247,254,268,273,285],"traditional":[62],"7+3":[63],"cytarabine/daunorubicin":[64],"chemotherapy":[65,242],"regimen":[66],"patients":[68,278],"with":[69,279],"acute":[70],"myeloid":[71],"leukemia":[72,216,251],"(AML).":[73],"The":[74,100],"notable":[75],"clinical":[76,182],"achieved":[81],"through":[82],"maintenance":[83],"synergistic":[86,202],"5:1":[87],"molar":[88,117],"ratio":[89,118,204],"within":[94,146],"liposome":[96,164,185],"after":[97,209],"intravenous":[98],"injection.":[99],"liposome,":[102,270],"which":[103,237],"formulated":[105],"contain":[107],"bilayers":[108],"distearoylphosphatidylcholine,":[110],"distearoylphosphatidylglycerol,":[111],"cholesterol":[113],"at":[114,125],"7:2:1":[116],"remains":[120],"in":[121,149,277,289],"gel":[123],"phase":[124],"body":[126],"temperature,":[127],"provides":[128],"stability":[129],"without":[130],"polyethylene":[131],"glycol,":[132],"controlled":[133],"release":[134],"daunorubicin,":[138],"limited":[139],"systemic":[140],"drug":[141,203,287],"distribution,":[142],"preferential":[144],"internalization":[145],"malignant":[147,228],"myeloblasts":[148],"bone":[151,257],"marrow":[152],"via":[153,230],"active":[154],"uptake":[155,212],"liposomes":[157,214],"into":[158],"cytoplasmic":[159],"vacuoles.":[160],"Thus,":[161],"protects":[165],"from":[169,253],"metabolism":[170],"elimination,":[172],"while":[173],"overcoming":[174],"pharmacokinetic":[175],"differences":[176],"between":[177],"two":[179],"agents.":[180],"studies,":[183],"these":[184],"properties":[186,266],"markedly":[187],"increased":[188],"elimination":[190],"half-life":[191],"versus":[194],"free":[195],"maintained":[200],"24":[207],"hrs":[208],"administration.":[210],"Preferential":[211],"by":[215],"cells":[217,229,252],"suggests":[218],"relatively":[220],"large":[221],"amounts":[222],"enter":[227],"liposomes,":[231],"bypassing":[233],"P-glycoprotein-based":[234],"efflux":[235],"pumps,":[236],"important":[239],"mediators":[240],"resistance,":[243],"contribute":[245,293],"rapid":[248],"clearance":[249],"circulation":[255],"marrow.":[258],"These":[259],"pharmacologic":[260],"advantages,":[261],"direct":[263],"consequence":[264],"encapsulating":[269],"may":[271],"explain":[272],"newly":[280],"diagnosed":[281],"high-risk/secondary":[282],"AML":[283],"reduced":[286],"exposure":[288],"off-target":[290],"tissues":[291],"manageable":[296],"safety":[297],"profile.":[298]},"counts_by_year":[{"year":2026,"cited_by_count":18},{"year":2025,"cited_by_count":17},{"year":2024,"cited_by_count":21},{"year":2023,"cited_by_count":14},{"year":2022,"cited_by_count":24},{"year":2021,"cited_by_count":20},{"year":2020,"cited_by_count":22},{"year":2019,"cited_by_count":2}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2019-05-29T00:00:00"}